Skip Navigation

JNCI Journal of the National Cancer Institute 1991 83(4):285-288; doi:10.1093/jnci/83.4.285
© 1991 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Logothetis, C. J.
Right arrow Articles by Amato, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Logothetis, C. J.
Right arrow Articles by Amato, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 83, No. 4, 285-288, February 20, 1991
© 1991 Oxford University Press

Fluorouracil and Recombinant Human Interferon Alfa-2a in the Treatment of Metastatic Chemotherapy-Refractory Urothelial Tumors

Christopher J. Logothetis*, Elizabeth Hossan, Avishay Sella, Francisco H. Dexeus,, R. J. Amato

Department of Medical Oncology, The Unviersity of Texas M. D. Anderson Cancer Center Houston , tex

*Correspondence to: Christopher J. Logothetis, MD, Genitourinary Oncology, Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center,1515 Holcombe Blvd, Houston, TX 77030.

Thirty patients with advanced metastatic and chemotherapy-refractory urothelial tumors received a combination of fluorouracil (5-FU) and recombinant human interferon alfa-2a. Thirty-six sites of metastases were present in the 30 study patients, and the median Eastern Cooperative Oncology Group performance status was 3 (range, 1 to 4). All patients had failed to respond to primary combined methotrexate/cisplatin-based chemotherapy. Nine (30%; confidence interval, 15% to 47%) of the patients achieved a partial response. The mean duration of response was more than 5.2 months (median, 6 months; range, 3 to 8 months). Two patients who achieved a partial response of 5 and 7 months' duration, respectively, had control of residual disease (one with radiation and one with surgical excision) and have remained disease-free for an additional period of more than 7 and 13 months, respectively. These data suggest that the combination of 5-FU and recombinant human interferon alfa-2a is synergistic, with clinical significance for the treatment of urothelial tumors. The response rate for this combination of drugs is higher than that anticipated for either of these agents used alone. Additional confirmatory trials are needed to evaluate the significance of these findings. [J Natl Cancer Inst 83: 285–288, 1991]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.